Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes (Q37641377)

21 August 2017

1 reference

title

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes (English)

1 reference

21 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Carolyn F Deacon

1

0 references

Jens Juul Holst

object named as

Jens J Holst

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

133-140

1 reference

21 August 2017

1

1 reference

Therapeutic strategies based on glucagon-like peptide 1.

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Seprase: an overview of an important matrix serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903463862

10.1517/13543780903463862

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19947894